Tags

Type your tag names separated by a space and hit enter

[The first clinical experiences in Hungary with a new effective antibiotic (linezolid) effective against Gram-positive infections].
Orv Hetil 2003; 144(1):29-33OH

Abstract

INTRODUCTION

The occurrence of gram-positive infections caused by multiresistant organisms has increased significantly in general, particularly among the surgical patients, and only a few effective antibiotics are available. A new and effective, synthetic antibiotic, against gram-positives is the oxazolidinon group, that electively inhibits bacterial protein synthesis in the early phase. Linezolid, the first member of this group to be used in clinical practice is the linezolid was studied.

AIMS

The purpose of this study was to evaluate the effectiveness and safety of linezolid in the gram-positive infections of surgical patients.

METHODS

A 3rd phase, clinical trial was conducted at the Semmelweis University Ist Surgical Department in the period of 1999-2001. Twenty-one patients with gram-positive infections were enrolled to this study. The mean of age was 57 years. Patients were selected for linezolid treatment in whom the conventional anti-gram-positive antibiotic therapy caused difficulties.

RESULTS

Sixteen patients out of 21 recovered, one patient was cured clinically, but not microbiologically, and one case showed microbiological cure with clinical failure. In one case the methicillin resistant Staphylococcus aureus carriership was cured. Two cases had a fatal outcome. The causes of death were mediastinitis plus pneumonia in one case, and diffuse peritonitis with renal insufficiency in the other. Withdrawal from the study occurred in one case, due to drug intolerance.

CONCLUSIONS

The linezolid administration proved to be safe and effective even in those cases, in which either hypacusis or decreased renal function persisted, or oral intake was advantagous. Contraindication of linezolid therapy did not occur. Few side effects were observed. If the infection was polymicrobial, the linezolid could be combined with other antibiotics. Further investigations are mandatory to evaluate the role of linezolid in the treatment of methicillin resistant Staphylococcus aureus carriership.

Authors+Show Affiliations

Semmelweis Egyetem, Altalános Orvostudományi Kar, I. Sebészeti Klinika, Budapest. pi@seb1.sote.huNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Clinical Trial, Phase III
Controlled Clinical Trial
English Abstract
Journal Article
Multicenter Study

Language

hun

PubMed ID

12635350

Citation

Pulay, István, et al. "[The First Clinical Experiences in Hungary With a New Effective Antibiotic (linezolid) Effective Against Gram-positive Infections]." Orvosi Hetilap, vol. 144, no. 1, 2003, pp. 29-33.
Pulay I, Konkoly TM, Zsirka KA, et al. [The first clinical experiences in Hungary with a new effective antibiotic (linezolid) effective against Gram-positive infections]. Orv Hetil. 2003;144(1):29-33.
Pulay, I., Konkoly, T. M., Zsirka, K. A., Csapó, Z., Flautner, L., & Tihanyi, T. (2003). [The first clinical experiences in Hungary with a new effective antibiotic (linezolid) effective against Gram-positive infections]. Orvosi Hetilap, 144(1), pp. 29-33.
Pulay I, et al. [The First Clinical Experiences in Hungary With a New Effective Antibiotic (linezolid) Effective Against Gram-positive Infections]. Orv Hetil. 2003 Jan 5;144(1):29-33. PubMed PMID: 12635350.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [The first clinical experiences in Hungary with a new effective antibiotic (linezolid) effective against Gram-positive infections]. AU - Pulay,István, AU - Konkoly,Thege Marianne, AU - Zsirka,Klein Attila, AU - Csapó,Zsolt, AU - Flautner,Lajos, AU - Tihanyi,Tibor, PY - 2003/3/15/pubmed PY - 2003/4/24/medline PY - 2003/3/15/entrez SP - 29 EP - 33 JF - Orvosi hetilap JO - Orv Hetil VL - 144 IS - 1 N2 - INTRODUCTION: The occurrence of gram-positive infections caused by multiresistant organisms has increased significantly in general, particularly among the surgical patients, and only a few effective antibiotics are available. A new and effective, synthetic antibiotic, against gram-positives is the oxazolidinon group, that electively inhibits bacterial protein synthesis in the early phase. Linezolid, the first member of this group to be used in clinical practice is the linezolid was studied. AIMS: The purpose of this study was to evaluate the effectiveness and safety of linezolid in the gram-positive infections of surgical patients. METHODS: A 3rd phase, clinical trial was conducted at the Semmelweis University Ist Surgical Department in the period of 1999-2001. Twenty-one patients with gram-positive infections were enrolled to this study. The mean of age was 57 years. Patients were selected for linezolid treatment in whom the conventional anti-gram-positive antibiotic therapy caused difficulties. RESULTS: Sixteen patients out of 21 recovered, one patient was cured clinically, but not microbiologically, and one case showed microbiological cure with clinical failure. In one case the methicillin resistant Staphylococcus aureus carriership was cured. Two cases had a fatal outcome. The causes of death were mediastinitis plus pneumonia in one case, and diffuse peritonitis with renal insufficiency in the other. Withdrawal from the study occurred in one case, due to drug intolerance. CONCLUSIONS: The linezolid administration proved to be safe and effective even in those cases, in which either hypacusis or decreased renal function persisted, or oral intake was advantagous. Contraindication of linezolid therapy did not occur. Few side effects were observed. If the infection was polymicrobial, the linezolid could be combined with other antibiotics. Further investigations are mandatory to evaluate the role of linezolid in the treatment of methicillin resistant Staphylococcus aureus carriership. SN - 0030-6002 UR - https://www.unboundmedicine.com/medline/citation/12635350/[The_first_clinical_experiences_in_Hungary_with_a_new_effective_antibiotic__linezolid__effective_against_Gram_positive_infections]_ DB - PRIME DP - Unbound Medicine ER -